MIAMI, Oct. 1, 2015—Global Stem Cells Group, has announced the launch of a new stem cell treatment center in Cochabamba, Bolivia. The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine to patients from around the world.

The opening of  the Cochabamba stem cell clinic is in association with aesthetic surgery specialist Katherine Antezana, and will provide adipose derived stem cell treatments for aesthetic and cosmetic procedures. Under the Global Stem Cells Group brand, the new clinic will initiate a study on the use of adipose stem cells for hair growth.

This latest clinic opening is part of GSCG’s continued  expansion in the region.
Global Stem Cells Group has been expanding its clinical presence worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics, licensed and developed under the GSCG banner.

Global Stem Cells Group provides stem cell treatments for a variety of diseases and conditions, including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and multiple sclerosis at various facilities worldwide. The new facility in Cochabamba will have an international staff that is experienced in administering the leading cellular therapies available.

Global Stem Cells Group’s Cochabamba, Bolivia clinic is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. GSCG clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

The Global Stem Cells Group is committed to providing the highest of standards of services and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call +1 305 560 5337.

About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
###

MIAMI, Oct. 26, 2015—Global Stem Cells Group has announced that Alfredo Hoyos, M.D., head of the Global Stem Cells Group Faculty, will be keynote speaker at the 2nd Aesthetic & Anti-aging Medicine World Congress (AMWC) – Latin America, to be held in Medellin, Colombia Nov. 5, 6 and 7, 2015. The conference will focus on aesthetic dermatology and surgery, preventive and anti-aging medicine.
Hoyos, founder of Stemlab.com and the inventor of High Definition Liposculpture (HDL), Dynamic Definition Lipoplasty (4D), and other advanced techniques in body contouring, will present his curriculum, “Advanced Liposuction 4D: Evolution and State of the Art state-of-the-art Techniques,” combining VASER technology with other techniques. Hoyos will also be participating in the event’s half-day program dedicated to body contouring through liposuction surgery.

The conference will be a one-of-a-kind event, the largest international event in the field of aesthetic and anti-aging medicine, designed to showcase AWMC Latin America’s commitment to innovation, expertise and excellence by sharing a wealth of experience as well as teaching skills to medical professionals from around the world. The conference’s prestigious lineup of international faculty members will contribute to the enhancement of knowledge and skills for all attending practitioners.

The conference will offer a number of advanced academic and clinical sessions with lectures presented by prominent experts in the field of aesthetic and anti-aging medicine as well as from research centers and universities. Maritza Novas, R.N., M.S.N., lead trainer with GSCG subsidiary Stem Cells Training, will speak on the use of fat stem cells for tissue regeneration.

Participants will have an opportunity to meet representatives from companies and manufacturers in the medical industry during breaks offered on site. A large exhibition will showcase the services and products of leading aesthetic and anti-aging professionals and companies from around the world.
The 2nd AMWC – Aesthetic & Anti-Aging Medicine World Congress – Latin America will be held at the Main Square Convention Center (Plaza Mayor Convenciones) in Medellion. For more information, visit the AMWC website, email bnovas(at)stemcellsgroup(dot)com, or call +1 305 560 5337.

About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About Alfredo Hoyos, M.D.:
Alfredo Hoyos, M.D., has been an active member of the GSCG team since signing on as an exclusive representative for the stem cell leader’s Colombian territory in Sept., 2014. Hoyos was named the permanent head of the GSCG Faculty in Oct., 2015.

The Global Stem Cells Group / Stem Cell Training Faculty consists of a distinguished board of physicians, all experts in stem cell and regenerative medicine. The faculty reviews, updates and makes decision pertaining to the training programs offered through the Stem Cell Training division of Global Stem Cells Group. Faculty members also share the latest hand-on techniques and technologies with physicians, nurses, and other health care professionals through SCT’s instructional stem cell training courses.

Hoyos divides his time between practices in Miami and Bogota, Colombia. He is the founder of Stemlab, a Bogota, Colombia company dedicated to furthering the development of aesthetic techniques using stem cell (stromal) derived from adipose tissue. Stemlab is currently conducting extensive research in regenerative medicine in an effort to establish stem cell treatments that can repair damaged tissue in living organisms, using natural biological mechanisms that are proving useful in auto repair processes on damaged tissue.

About Maritza Novas, R.N., M.S.N.:
Maritza Novas, R.N., M.S.N. is the lead trainer and member member of the research and development of Stem Cell Training, a subsidiary of Global Stem Cells Group, specializing in:
•  Functional medicine
•  Age management
•  Bio-identical hormone therapy
•  Weight control
•  Rejuvenation.

A certified Adistem Specialist for more than four years, Ms. Novas has performed more than 600 treatments involving a range of pathologies.

Novas has been responsible for successfully training and certifying more than 150 stem cell practitioners globally, and has assisted in the development of new proprietary adipose and bone marrow protocols currently being used in Stem Cell Training Inc. comprehensive courses. She is a member of the American Academy of Anti-aging Medicine.

MIAMI, Oct. 26, 2015—Global Stem Cells Group, a world leader in regenerative medicine, has announced its participation in the 20th World Congress of Aesthetic Medicine, to be held at the JW Marriott in Miami Nov. 12-15, 2015. Faculty from Stem Cell Training, a GSCG subsidiary, will be sharing the latest hands-on techniques and protocols for in-office stem cell harvesting procedures.

The 20th World Congress of Aesthetic Medicine will gather aesthetic medicine experts and thought leaders from around the world to provide prospective on the industry’s future, and identify where key opportunities can be found. The theme of this conference, “Discoveries in Aesthetic Medicine,” is designed to educate practitioners on the latest procedures, products and technologies available in this fast-growing market.

Key stem cell medicine researchers, practitioners and industry insiders from around the world will gather to meet, network and participate in the congress, exhibition, social events, pre-congress courses and a post-congress CME Western Caribbean cruise. Simultaneous English-Spanish-English interpretation will be featured in the main conference room.

The American Academy of Aesthetic Medicine was selected by the UIME (Union Internationale de Médecine Esthétique/International Association of Aesthetic Medicine) to host the event. The popularity of minimally invasive aesthetic medicine procedures in a clinical setting has grown immensely in the U.S. and globally. The specialty is attracting a growing community of physicians and industry suppliers worldwide as opportunities in aesthetic medicine continue to proliferate.
For more information on the 20th World Congress of Aesthetic Medicine, visit the aaamed.org website, email bnovas(at)stemcellsgroup(dot)com, or call +1 305 560 5337.

About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About Stem Cell Training, Inc.:
Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

The company’s training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.’s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.

About AAAM:
The American Academy of Aesthetic Medicine (AAAM) is dedicated to teaching physicians who have a scientific and clinical interest in exploring the aesthetic medicine element of their practice. AAAM teaches the art, science, techniques and procedures of aesthetic medicine to licensed physicians, regardless of specialty. AAAM provides education and hands-on training, and disseminates leading edge information gathered from advances in North America and around the world to its members.

AAAM has trained more than 5,000 doctors since 1999 from the United States, Mid-East, Asia, Australia, South Africa, and Europe. AAAM has conducted more than 300 courses including congresses across the globe since its inception. The AAAM is the exclusive USA member of the International Union of Aesthetic Medicine (UIME), which is comprised of 29 member societies and 30,000 members. AAAM’s President Emeritus Michel Delune, M.D. is one of the original four founding members of the UIME, and is founder of the American Academy of Aesthetic Medicine.

Adimarket, Inc., a leading provider of in-office regenerative medicine solutions, has announced a collaborative agreement with Korean biomedical and lab equipment manufacturer N-Biotek to promote and distribute their stem cell technology equipment throughout Latin America.

N-Biotek is a leading manufacturer of biomedical and lab equipment worldwide. The company develops a range of custom lab products including:

• Tabletop incubators used for suspension cell culture in microbiology and molecular biology research.
• The DNA-VAC, used to extract DNA< RNA< amino acids, proteins, hormones and enzymes quickly and efficiently.
• A multi-functional, bio-work cell station with built-in centrifuge, shaking incubator and particle meter for stem cell isolation and handling.
• A small, remote shaker, compact and easy to move.
• A biological safety cabinet, dying oven, high pressure steam sterilizer, PCR work station, tabletop bio-work station, tabletop vacuum clave and vertical autoclave.

N-Biotek is the only company that builds the whole stem cell processing system for partners ready to begin work in the stem cell industry. N-Biotek meets every need for stem cell clinicians, including biological clean room construction, equipment installation and stem cell processing consulting.

“Our main objective is to supply a complete selection of biomedical and lab instruments that are designed to create a personal laboratory, a concept we call, “Handy Lab,” says N-Biotek Director Sanguk Ra. “All of our products are customized and compact, which is why our new alliance with AdiMarket in South America makes perfect sense,” he says.

“Adimarket can help us distribute our laboratory equipment to clinicians and medical facilities in major cities and even in the most remote areas of Latin America.”

N-Biotek currently distributes medical equipment and services to facilities and professionals in more than 100 countries.

For more information, visit the Adimarket website, email info(at)adimarket(dot)net, or call +1 305 560 5337.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.

Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.

About the Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About N-Biotek:

N-Biotek, Inc., founded in 2000 and located in the Gyeonggi-do Province of South Korea, is a leading manufacturer and supplier of bio-technology-related laboratory equipment. N-Biotek delivers high quality biomedical equipment to more than 100 countries.

###

Adimarket, Inc., a leading provider of in-office regenerative medicine solutions, has reached an agreement with MyStem to promote and distribute their stem cell technology products throughout Latin America.

MyStem develops and manufactures regenerative products for use in orthobiologics (ortho, trauma, spine), sports medicine, plastic surgery, aesthetics and dermatology treatments.

MyStem products include the innovative adipose-derived regenerative fraction device MyStem X2, a disposable collection and separation system for autologous adipose-derived mesenchymal stem cells (AdMSC). The MyStem device collects regenerative fraction without any extensive tissue manipulation, according to requirements established under international laws, in a completely safe closed sterile system. The regenerative fraction separation process is based on cells intrinsic parameters in a liquid fraction according to fluidic laws.

After the separation process, a concentrated regenerative cells fraction suspension is ready for use in a one-step procedure. MyStem offers an enhanced method for isolating and quickly expanding a robust population of mesenchymal stem cells (MSCs) derived from lipoaspirate in less than 30 minutes. This isolation process yields a generous population of ASCs (~100,000 cells per 100 ml of blood/saline collected from sonicated lipoaspirate) with differentiation potential, characteristic cell surface markers, and proliferative lifespan indistinguishable from MSCs extracted from bone marrow (BMSCs) or conventionally processed ASCs.(1,2 ).

The MyStem process is simple, with no centrifuge needed. Quality sampling is not operator dependent, and collects up to 1,000 times more than the bone marrow MSC + growth factors.

MyStem Managing Director Pier Ivona calls the new alliance with Adimarket a natural fit, since both companies share a deep commitment to getting critical regenerative medicine tools to the clinicians in Latin America who need them.

“Global Stem Cells Group and MyStem are both pioneers in stem cell research and innovation, and we share the same goal of making stem cell therapies available globally,” Ivona says. “We believe that this is the perfect time to team with Global Stem Cells Group and its Adimarket division to distribute MyStem technology throughout Latin America’s fast-growing medical community.”

The collaboration between Global Stem Cells Group and MyStem reflects one more step toward GSCG’s commitment to expanding its presence in communities that need and deserve access to cutting-edge regenerative medicine, not only in Latin America but also worldwide.

For more information, visit the Adimarket website, email info(at)adimarket(dot)net, or call +1 305 560 5337.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.
Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.

Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.

About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About MyStem:

Wilmington, Delaware-based MyStem is dedicated to contributing to human welfare through the design, manufacture, and sale of regenerative medicine instruments or appliances designed to alleviate pain and restore health. MyStem specializes in regenerative medicine treatments for: spine, ortho, sports medicine, burn and wound healing, CMF (cranio maxillo facial), chronic wounds and diabetic foot wounds.

###

MIAMI, Oct. 5, 2015— Global Stem Cells Group has announced that Augusto Brazzini, M.D., president of the Peruvian Society for Cellular Therapy, will appear as a featured lecturer at the Global Stem Cells Group Buenos Aires Symposium on Oct. 15, 2015.

Brazzini, a renowned physician and stem cell scientist, also founded the Brazzini Institute of Interventional Radiology in San Isidro, Peru.  Brazzini will speak on the latest advancements in clinical applications for hematopoietic stem cells to treat Parkinson’s Disease and other chronic conditions.
He is also a professor at San Martin University in Lima, and vice president of  the Peruvian Association of Cell Therapy (APTCEL,) a scientific and educational association created in Peru to promote the study, research and application of adult stem cell therapy.

Dr. Brazzini received his medical degree from Federicoima,  Villarreal National University in 1977 and received additional training in radiology from San Marcos National University Police Peruvian Hospital and National Institute of Neoplasic Diseases.
For more information on the Global Stem Cells Group Buenos Aires symposium including the lineup of speakers, visit the stemcellconference.org website, emailbnovas@stemcellsgroup.com, or call +1 305 560 5337.

About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
###

Global stem cells group and associate Burton Feinerman M.D. have announced plans to offer innovative stem cell therapies to treat patients with specific neurodegenerative conditions.

MIAMI AND TAMPA, FLA. (PRWEB) AUGUST 24, 2015

Global Stem Cells Group, has announced plans to collaborate with regenerative medicine specialist Burton Feinerman M.D. to offer new stem cell therapies that combine adult stem cells derived from adipose tissue, bone marrow and peripheral blood with differentiated cells and transference factors, using patented protocols developed by Feinerman.

The treatment protocols will target specific neurodegenerative conditions that primarily affect the neurons in the brain. Neurons are critical components of the nervous system, which includes the brain and spinal cord. When they become damaged die, neurons don’t reproduce or replace themselves. Examples of neurodegenerative diseases include Alzheimer’s and Parkinson’s disease.

Neurodegenerative diseases are incurable and debilitating conditions that lead to the progressive degeneration or death of nerve cells, causing difficulty with movement or mental function (dementia). According to a March, 2015 World Health Organization report, dementias are responsible for the greatest burden of disease with Alzheimer’s representing approximately 60-70 percent of cases.

Feinerman is a physician and research scientist specializing in stem cell therapies, ant-aging medicine and gene therapies to treat a variety of conditions and diseases. He is a member of the GSCG Advisory Board.
For more information on innovative stem cell therapies, visit the Global Stem Cells Group Website, email bnovas@stemcellsgroup.com, or call 305-224-1858.

About the Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

To learn more about Global Stem Cells Group, Inc.’s companies and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About Burton Feinerman, M.D.:

Burton Feinerman, M.D. an internationally recognized expert in stem cell and gene therapy, helped pioneer the earliest patents for regenerative medicine therapies. He has dedicated his medical career to improving the lives of patients through regenerative medicine.

Feinerman earned a medical degree from New York Medical College and completed his fellowship at the renowned Mayo Clinic in Rochester, Minnesota. He has been practicing medicine for more than half a century and has dedicated his practice to bettering the lives of his patients through regenerative medicine. Feinerman believes in challenging the incurable with regenerative medicine, and providing a new pathway to overall health and longevity.

Feinerman is a highly respected board certified physician and a member of numerous medical societies including the Society of Apheresis, the Society of Bone Marrow Blood Transplantation, the International Society of Cellular Therapy, the Society for Cranial Transplantation and Brain Repair, the Society for Cardiac Translational Therapy. He is a member of the Global Stem Cells Group Advisory Board.